Certolizumab Pegol: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), NICE (England) and TLV (Sweden) recommended or restricted certolizumab pegol, while AOTMIT (Poland), AWMSG (Wales) and NYE METODER (Norway) did not recommend it.
HAS (France) has been harder on certolizumab pegol than on its own caseload: it refused 2 of 6 decisive submissions here (33%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 13.5 years separate the first record, 2 Sep 2009 at AWMSG (Wales), from the most recent, 20 Mar 2023 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: not recommended on 7 Jun 2010, restricted by 8 Apr 2019, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for certolizumab pegol, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The programme is broad: 13 distinct indication wordings are recorded for certolizumab pegol by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 43 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess certolizumab pegol, on 2 Sep 2009; PHARMAC (New Zealand) did not open a file until 20 Mar 2023 — an unusually long tail of 13.5 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 13 years in total.
8 of the 11 agencies here assessed certolizumab pegol more than once, CONITEC (Brazil) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for certolizumab pegol.
The full ledger for certolizumab pegol reads 15 recommended, 13 not recommended, 5 other and 4 restricted, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 20 Mar 2023 | Rheumatoid athritis | PTAC advice: No Formal Recommendation · decision reached | source |
| CONITEC (Brazil) | 27 Sep 2022 | Tratamento de pacientes acima de 18 anos com psoríase em placas moderada a grave e peso inferior à 90kg e Não respondera… | not incorporated | source |
| HAS (France) | 11 Jul 2022 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| AOTMIT (Poland) | 2 Aug 2019 | programu lekowego „Leczenie umiarkowanej i ciężkiej postaci łuszczycy plackowatej (ICD-10 L 40.0) | not recommended | source |
| PBAC (Australia) | 2019 | Non-radiographic axial spondyloarthritis (nraxSpA) | The PBAC recommended the Authority Required listing of certolizumab pegol for the treatmen… | source |
38 further decisions for certolizumab pegol, across 10 agencies, are not shown here. They link to 20 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 43 decisions for certolizumab pegol from 11 agencies, 2009 to 2023. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.